Neurogene, Inc. Common Stock

NGNENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
38.41 USD
↘ 2.43 (5.95%)AT CLOSE (11:59 AM EDT)
38.35
↘ 0.06 (0.17%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
38.35
↘ 0.06 (0.17%)
🔴Market: CLOSED

Neurogene, Inc. Common Stock (NGNE) is currently trading at $38.48. NGNE shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, NGNE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 26, 2026.

Open?$40.74
High?$41.77
Low?$38.27
Prev. Close?$40.84
Volume?180.2K
Avg. Volume?208.1K
VWAP?$39.40
Rel. Volume?0.87x
Bid / Ask
Bid?$30.95 × 100
Ask?$45.00 × 100
Spread?$14.05
Midpoint?$37.98
Valuation & Ratios
Market Cap?768.6M
Shares Out?20.0M
Float?10.7M
Float %?67.6%
P/E Ratio?N/A
P/B Ratio?3.54
EPS?-$5.55
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
131
Market Cap
817.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.neurogene.com
Listed
2023-12-19
Address
535 W 24TH STREET
NEW YORK, NY 10011
Phone: (877) 237-5020
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?13.92Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.45%Squeeze Risk
Short Interest?3.0M
Days to Cover?16.8
Free Float10.7M
Avg Daily Volume180.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?10.64Strong
Quick Ratio?10.64Strong
Cash Ratio?5.23Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
49
3.54FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-51.2%WEAK▾
ROA?
S&P
3
-45.5%WEAK▾
Cash Flow & Enterprise
FCF?$-87707000
Enterprise Value?$656.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist